339290-21-0

Basic information

• Product Name: 7-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)-amino]-quinoline-3-carboxylic acid ethyl ester
• Synonyms: 7-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)-amino]-quinoline-3-carboxylic acid ethyl ester
• CAS NO: 339290-21-0
• Molecular Weight: 464.444
• Mol File: 339290-21-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 7-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)-amino]-quinoline-3-carboxylic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 7-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)-amino]-quinoline-3-carboxylic acid ethyl ester(339290-21-0)
• EPA Substance Registry System: 7-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)-amino]-quinoline-3-carboxylic acid ethyl ester(339290-21-0)

Safety Data

• Hazardous Substances Data: 339290-21-0(Hazardous Substances Data)

Upstream product

• 339290-20-9 7-Amino-quinoline-3-carboxylic acid ethyl ester 
• 108-20-3 di-isopropyl ether 
• 180340-74-3 4'-trifluoromethylbiphenyl-2-carbonyl chloride 
• 1122-58-3 dmap 

Downstream Products

• 339290-22-1 7-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-quinoline-3-carboxylic acid 

Relevant articles and documents

7[4′-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and method of inhibiting the secretion of apolipoprotein B

This invention relates to compounds of Formula I that inhibit the secretion of apolipoprotein B, to pharmaceutical compositions comprising the compounds, and to methods of treating and/or preventing atherosclerosis, obesity, diabetes, hyperlipidemia, hyperliproproteinemia, hypercholesterolemia, hypertriglyceridemia, hypoalphalipoproteinemia, pancreatitis, myocardial infarction, stroke, restenosis, or Syndrome X. This invention also relates to methods of reducing the secretion of apolipoprotein B and/or inhibiting microsomal triglyceride transfer protein.

Methods of administering apo B-secretion/MTP inhibitors

The invention provides methods for administering of apolipoprotein B-secretion (Apo B)/microsomal triglyceride transfer protein (MTP) inhibitors which comprise administering the inhibitor to a subject in need of treatment therewith prior to, or during, a